Biocompatible low-retention superparamagnetic iron oxide nanoclusters as contrast agents for magnetic resonance imaging of liver tumor

Journal of Biomedical Nanotechnology

Volumn 11, Issue 5, 2015, Pages 854-864

  Wei, Yushuang ^a   Liao, Rufang ^b   Liu, Haijuan ^a   Li, Huan ^b   Xu, Haibo ^b   Zhou, Qibing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bioclearance; Contrast agent; Liver tumor imaging; Magnetic resonance imaging; Superparamagnetic iron oxide nanoparticles; Urine excretion

Indexed keywords

AMINO ACIDS; BIOCOMPATIBILITY; BODY FLUIDS; IRON; MAGNETIC RESONANCE IMAGING; NANOCLUSTERS; NANOMAGNETICS; NANOPARTICLES; PHYSIOLOGY; RESONANCE; STARCH; SUPERPARAMAGNETISM; TUMORS;

BIOCLEARANCE; CONTRAST AGENT; LIVER TUMORS; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; URINE EXCRETION;

IRON OXIDES;

CONTRAST MEDIUM; HETASTARCH; NANOPARTICLE; OLEIC ACID; POLYLYSINE; POLYMER; REACTIVE OXYGEN METABOLITE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; BIOMATERIAL; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; HYDRODYNAMICS; IRON BLOOD LEVEL; IRON OVERLOAD; LIVER TUMOR; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; URINARY EXCRETION; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; DIAGNOSTIC USE; HUMAN; LIVER NEOPLASMS; MATERIALS TESTING; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELLS, CULTURED; CONTRAST MEDIA; FERRIC COMPOUNDS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MATERIALS TESTING; MICE; MICE, INBRED BALB C; PARTICLE SIZE; POLYLYSINE;

EID: 84918492277     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2042     Document Type: Article

References (44)

1. Y. X. Wang, S. M. Hussain, and G. P. Krestin, Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11, 2319 (2001).
2. J. E. Rosen, L. Chan, D.-B. Shieh, and F. X. Gu, Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine 8, 275 (2012).
3. P. F. Hahn, D. D. Stark, J. M. Lewis, S. Saini, G. Elizondo, R. Weissleder, C. J. Fretz, and J. T. Ferrucci, First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging. Radiology 175, 695 (1990).
4. R. Weissleder, G. Elizondo, J. Wittenberg, A. S. Lee, L. Josephson, and T. J. Brady, Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging. Radiology 175, 489 (1990).
5. H. Bernd, E. D. Kerviler, S. Gaillard, and B. Bonnemain, Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: Comprehensive analysis of a clinical development program. Invest. Radiol. 44, 336 (2009).
6. C. Yang, A. Rait, K. F. Pirollo, J. A. Dagata, N. Farkas, and E. H. Chang, Nanoimmunoliposome delivery of superparamagnetic iron oxide markedly enhances targeting and uptake in human cancer cells in vitro and in vivo. Nanomedicine 4, 318 (2008).
7. T. Koyama, M. Shimura, Y. Minemoto, S. Nohara, S. Shibata, Y. Iida, S. Iwashita, M. Hasegawa, T. Kurabayashi, H. Hamada, K. Kono, E. Honda, I. Aoki, and Y. Ishizaka, Evaluation of selective tumor detection by clinical magnetic resonance imaging using antibody-conjugated superparamagnetic iron oxide. J. Control. Release 159, 413 (2012).
8. L. Zhu, D. Wang, X. Wei, X. Zhu, J. Li, C. Tu, Y. Su, J. Wu, B. Zhu, and D. Yan, Multifunctional pH-sensitive superparamagnetic ironoxide nanocomposites for targeted drug delivery and MR imaging. J. Control. Release 169, 228 (2013).
9. Y. Ling, K. Wei, F. Zou, and S. Zhong, Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int. J. Pharm. 430, 266 (2012).
10. E. H. Chang, Nanomedicine-Basic and Clinical Applications in Diagnostics and Therapy, Else Kröner-Fresenius Symp. edited by C. Alexiou and A. G. Karger, Basel, Switzerland (2011), Vol. 2, p. 145.
11. X. Chen, H. Lv, M. Ye, S. Wang, E. Ni, F. Zeng, C. Cao, F. Luo, and J. Yan, Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: Preparation, characterization and double targeting. Int. J. Pharm. 426, 248 (2012).
12. S. Toki, R. A. Omary, K. Wilson, J. C. Gore, R. S. Peebles, Jr, and W. Pham, A comprehensive analysis of transfection-assisted delivery of iron oxide nanoparticles to dendritic cells. Nanomedicine 9, 1235 (2013).
13. Y. Mou, B. Chen, Y. Zhang, Y. Hou, H. Xie, G. Xia, M. Tang, X. Huang, Y. Ni, and Q. Hu, Influence of synthetic superparamagnetic iron oxide on dendritic cells. Int. J. Nanomedicine 6, 1779 (2011).
14. X. Wang, F. Wei, A. Liu, L. Wang, J.-C. Wang, L. Ren, W. Liu, Q. Tu, L. Li, and J. Wang, Cancer stem cell labeling using poly(Llysine)- modified iron oxide nanoparticles. Biomaterials 33, 3719 (2012).
15. B. Szalay, E. Tátrai, G. Nyír?o, T. Vezér, and G. Dura, Potential toxic effects of iron oxide nanoparticles in in vivo and in vitro experiments. J. Appl. Toxicol. 32, 446 (2012).
16. M. Mahmoudi, H. Hofmann, B. Rothen-Rutishauser, and A. Petri- Fink, Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem. Rev. 112, 2323 (2012).
17. T. K. Jain, M. K. Reddy, M. A. Morales, D. L. Leslie-Pelecky, and V. Labhasetwar, Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol. Pharm. 5, 316 (2008).
18. D. Pouliquen, J. J. L. Jeune, R. Perdrisot, A. Ermias, and P. Jallet, Iron oxide nanoparticles for use as an MRI contrast agent: Pharmacokinetics and metabolism. Magn. Reson. Imaging 9, 275 (1991).
19. S. H. Crayton, D. R. Elias, A. A. Zaki, Z. Cheng, and A. Tsourkas, ICP-MS analysis of lanthanide-doped nanoparticles as a nonradiative, multiplex approach to quantify biodistribution and blood clearance. Biomaterials 33, 1509 (2012).
20. J. D. López-Castro, A. V. Maraloiu, J. J. Delgado, J. J. Calvino, M.-G. Blanchin, N. Gálvez, and J. M. Domínguez-Vera, From synthetic to natural nanoparticles: Monitoring the biodegradation of SPIO (P904) into ferritin by electron microscopy. Nanoscale 3, 4597 (2011).
21. L. Gu, R. H. Fang, M. J. Sailor, and J. H. Park, In vivo clearance and toxicity of monodisperse iron oxide nanocrystals. ACS Nano 6, 4947 (2012).
22. H. Lee, E. Lee, K. D. Kim, N. K. Jang, Y. Y. Jeong, and S. Jon, Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J. Am. Chem. Soc. 128, 7383 (2006).
23. F. Roohi, J. Lohrke, A. Ide, G. Schütz, and K. Dassler, Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles. Int. J. Nanomedicine 7, 4447 (2012).
24. S. Saito, M. Tsugeno, D. Koto, Y. Mori, Y. Yoshioka, S. Nohara, and K. Murase, Impact of surface coating and particle size on the uptake of small and ultrasmall superparamagnetic iron oxide nanoparticles by macrophages. Int. J. Nanomedicine 7, 5415 (2012).
25. K. Tsuchiya, N. Nitta, A. Sonoda, A. Nitta-Seko, S. Ohta, H. Otani, M. Takahashi, K. Murata, K. Murase, S. Nohara, and K. Mukaisho, Histological study of the biodynamics of iron oxide nanoparticles with different diameters. Int. J. Nanomedicine 6, 1587 (2011).
26. D. R. Elias, A. Poloukhtine, V. Popik, and A. Tsourkas, Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine 9, 194 (2013).
27. E. K. Larsen, T. Nielsen, T. Wittenborn, L. M. Rydtoft, A. R. Lokanathan, L. Hansen, L. Østergaard, P. Kingshott, K. A. Howard, F. Besenbacher, N. C. Nielsen, and J. Kjems, Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. Nanoscale 4, 2352 (2012).
28. D. Simberg, J.-H. Park, P. P. Karmali, W.-M. Zhang, S. Merkulov, K. McCrae, S. N. Bhatia, M. Sailor, and E. Ruoslahti, Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 30, 3926 (2009).
29. B. A. Larsen, M. A. Haag, N. J. Serkova, K. R. Shroyer, and C. R. Stoldt, Controlled aggregation of superparamagnetic iron oxide nanoparticles for the development of molecular magnetic resonance imaging probes. Nanotechnology 19, 265102 (2008).
30. GLOBOCAN 2008. Liver Cancer Incidence and Mortality Worldwide in 2008. (International Agency for Research on Cancer). [updated 2013 Nov. 11]. Available from: Http://globocan.iarc.fr.
31. J. M. Llovet and J. Bruix, Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312 (2008).
32. M. Vivarelli, R. Montalti, and A. Risaliti, Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. World J. Gastroenterol. 19, 7316 (2013).
33. I. Joo and B. I. Choi, New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer 1, 94 (2012).
34. S. Bota, F. Piscaglia, S. Marinelli, A. Pecorelli, E. Terzi, and L. Bolondi, Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer 1, 190 (2012).
35. T. Murakami, Y. Imai, M. Okada, T. Hyodo, W.-J. Lee, M.-J. Kim, T. Kim, and B. I. Choi, Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: Toward improved treatment decisions. Oncology 81, 86 (2011).
36. Q. Wei, D. Zhang, A. Yao, L. Mai, Z. Zhang, and Q. Zhou, Design, synthesis, and in vitro and in vivo biological studies of a 3-deoxythymidine conjugate that potentially kills cancer cells selectively. PLoS One 7, e52199 (2012).
37. S. Sun, H. Zeng, D. B. Robinson, S. Raoux, P. M. Rice, S. X. Wang, and G. Li, Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J. Am. Chem. Soc. 126, 273 (2004).
38. H. G. Cha, D. K. Lee, Y. H. Kim, C. W. Kim, C. S. Lee, and Y. S. Kang, Solventless nanoparticles synthesis under low pressure. Inorg. Chem. 47, 121 (2008).
39. L. K. Limbach, P. Wick, P. Manser, R. N. Grass, A. Bruinink, and W. J. Stark, Exposure of engineered nanoparticles to human lung epithelial cells: Influence of chemical composition and catalytic activity on oxidative stress. Environ. Sci. Technol. 41, 4158 (2007).
40. P. T. Schumacker, Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 10, 175 (2006).
41. L. Mai, A. Yao, J. Li, Q. Wei, M. Yuchi, X. He, M. Ding, and Q. Zhou, Cyanine 5.5 conjugated nanobubbles as a tumor selective contrast agent for dual ultrasound-fluorescence imaging in a mouse model. PLoS One 8, e61224 (2013).
42. G. Liu, H. Yang, X. M. Zhang, Y. Shao, and H. Jiang, MR imaging for the longevity of mesenchymal stem cells labeled with poly- L-lysine-Resovist complexes. Contrast Media Mol. Imaging 5, 53 (2010).
43. G. B. Lehmann, F. Asskali, M. Boll, M. A. Burmeister, G. Marx, R. Hilgers, and H. Förster, HES 130/0.42 shows less alteration of pharmacokinetics than HES 200/0.5 when dosed repeatedly. Br. J. Anaesth. 98, 635 (2007).
44. G. Minotti, Sources and role of iron in lipid peroxidation. Chem. Res. Toxicol. 6, 134 (1993).